CE: New Insulin/GLP-1RA Agents: Overview for the Pharmacist
Abstract
Diabetes is a rapidly growing disease that is progressive in nature. Many medications are approved for the treatment of diabetes however, several novel agents show improved efficacy and safety over current therapies. In late 2016, two novel diabetic agents became available, insulin glargine and lixisenatide and insulin degludec and liraglutide. These medications combine basal insulin and a glucagon-like peptide-1 receptor agonist and were approved by the FDA to improve glycemic control in patients with Type 2 Diabetes Mellitus. Both products have shown benefits to patients during clinical trials. This review will discuss characteristics of each agent and where the use of these drugs may be implemented into current treatment guidelines.
Full Text
Vol2Article2.pdf | |
File Size: | 690 kb |
File Type: |